ASH 2018 Annual Meeting Highlights in Hodgkin Lymphoma


Combination of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with RR HL
– Catherine Diefenbach, MD

Begin


Nivolumab for RR cHL after Autologous Hematopoietic Cell Transplantation
– Andreas Engert, MD

Begin


Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group
– Andreas Engert, MD

Begin


Results of a Phase II Intergroup Trial on B-CAP in Older Patients with Advanced-Stage HL
– Andreas Engert, MD

Begin


Detailed Analysis from the Phase 3 ECHELON-1 Study of Older Patients with Previously Untreated cHL
– Andrew M. Evens, DO, MSc, FACP

Begin


Response-Adapted Therapy for Stage III/IV HL Demonstrates Limitation of PET-Adapted Approach
– Andrew M. Evens, DO, MSc, FACP

Begin


Brentuximab Vedotin in Combination with Nivolumab or Chemotherapy in R/R Patients or AYA Patients
– Julie M. Vose, MD, MBA

Begin

Managing HL would like to recognize and thank Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics for their educational support of ManagingHodgkinLymphoma.com in 2018.

©2019 MediCom Worldwide, Inc. All rights reserved